Zusammenfassung
Betarezeptorenblocker hemmen die Funktion des sympathischen Nervensystems in allen Organen, die mit adrenergen Betarezeptoren ausgestattet sind. Dazu gehören insbesondere das Herz, die Nieren und die glatte Muskulatur von Bronchien und Muskelgefäßen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß;-adrenergic blockers? BMC Clin Pharmacol 7:4.
Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, NeuIsenburg: S 597-628.
Bell DS, Lukas MA, Holdbruck FK, Fowler MB (2006): The effect of carvedilol on mor- tality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22: 287-296.
Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebi- volol. Brit J Clin Pharmacol 38: 199-204.
Brodde OE (1991): Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203-242.
Chobanian AV, et al (2004): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). NIH No.04-5230, update of the JNC7 Report. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf.Aufgerufen 29.4.2011.
CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a rando- mised trial. Lancet 353: 9-13.
Dargie HJ (2003): ß;-Blockers in heart failure. Lancet 362: 2-3.
Deutsche Hochdruckliga - Deutsche Hypertonie Gesellschaft (2008): Leitlinien zur Behandlung der arteriellen Hypertonie. Stand Juni 2008. http://www.leitlinien. net/046-001.pdf.
Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 229-243.
Flather MC, Shibata MC, Coats AJS et al (2005): Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215-225.
Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic ac- tion of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001-1007.
Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245-257.
Hoppe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35: 535-541.
Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197-218.
Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545-1553.
McMurray J (2005): Making sense of SENIORS. Eur Heart J 26: 203-206.
MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001-2007.
Moen MD, Wagstaff AJ (2006): Nebivolol - a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389-1409.
National Institute of Health and Clinical Excellence (NICE) (2006): Management of hypertension in adults in primary care: partial update. Im Internet unter: guidance. nice.org.uk/CG34/niceguidance/pdf/English
Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658.
Poole-Wilson PA, Svedberg K, Cleland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13.
POISE Study Group (2008): Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839-1847.
Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19-27.
Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006.
Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511-514.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Medizin Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Lemmer, B. (2012). Betarezeptorenblocker. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-29242-2_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29241-5
Online ISBN: 978-3-642-29242-2
eBook Packages: Medicine (German Language)